SWITCH THERAPEUTICS
Company Snapshot
Founded: 2020
Entity Type: Private
Region: U.S.
Headquarter: California, U.S.
Key Geographics: U.S.
Corporate Address: 241 E. Harris Ave South San Francisco, California 94080 U.S. Tel. www.switchthera.com
Company Overview
Switch Therapeutics, founded in 2020, harnesses RNAi research from Caltech, Harvard Medical School, and City of Hope. In early 2022, after raising $52 Mn and moving into its own facility in South San Francisco, it publicly launched. Utilizing its proprietary CASi platform, Switch combines single and double-stranded RNAs for efficient self-delivery and uptake, potent gene knockdown, and cell selectivity. It focuses on precision RNAi therapies for central nervous system (CNS) diseases, using Conditionally Activated siRNAs (CASi), a novel class of drugs that employ siRNA structures with added extensions for molecular “switch” docking.
SWITCH THERAPEUTICS In News
Company's Business Segments
- Products : The company generates revenue through CASi platform.
Applications/End User Industries
- Healthcare
- Biotechnology
BCC Research Beacon 